22.12.2016 • News

Technip and BP Extend Alliance to Acetic Acid

(c) BP
(c) BP

French engineering group Technip and UK energy company BP have extended their alliance on purified terephthalic acid (PTA) to include acetic acid. Under the deal, Technip will be the exclusive provider of front-end loading (FEL) services for fully owned and joint-venture projects developed by BP worldwide. The acetic acid alliance will be managed out of Technip’s center in Rome, Italy, and will exploit existing synergies with the PTA relationship.

BP’s acetic acid technology portfolio comprises its Cativa XL process based on methanol carbonylation and the SaaBre process based on syngas. Charles Damianides, technology vice president at BP Petrochemicals, said it looks forward to replicating the success of its long-term PTA alliance with Technip in the acetic acid business.

Technip and BP extended their PTA alliance in December 2013 after the UK energy group decided to make its technology available for licensing to external third-parties. As a result, Technip became the exclusive provider of front-end engineering and design (FEED) for inside battery limits to BP for licensing. The original alliance was formed in 2000 with Technip providing FEED services for BP’s PTA projects.

Through its relationship with BP, the Paris-headquartered contractor has engineered approximately 8m t/y of PTA capacity spread over 20 projects.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.